Literature DB >> 31186839

The new standard of HCV therapy: Retreatment in experienced patients.

Naveen Gara1, Marc G Ghany1.   

Abstract

Entities:  

Year:  2012        PMID: 31186839      PMCID: PMC6490697          DOI: 10.1002/cld.4

Source DB:  PubMed          Journal:  Clin Liver Dis (Hoboken)        ISSN: 2046-2484


× No keyword cloud information.
  19 in total

1.  Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C.

Authors:  Mitchell L Shiffman; Marc G Ghany; Timothy R Morgan; Elizabeth C Wright; Gregory T Everson; Karen L Lindsay; Anna S F Lok; Herbert L Bonkovsky; Adrian M Di Bisceglie; William M Lee; Jules L Dienstag; David R Gretch
Journal:  Gastroenterology       Date:  2006-11-11       Impact factor: 22.682

2.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

3.  Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.

Authors:  Bruce R Bacon; Mitchell L Shiffman; Flavia Mendes; Reem Ghalib; Tarek Hassanein; Giuseppe Morelli; Shobha Joshi; Kenneth Rothstein; Paul Kwo; Norman Gitlin
Journal:  Hepatology       Date:  2009-06       Impact factor: 17.425

4.  Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.

Authors:  Adrian M Di Bisceglie; Mitchell L Shiffman; Gregory T Everson; Karen L Lindsay; James E Everhart; Elizabeth C Wright; William M Lee; Anna S Lok; Herbert L Bonkovsky; Timothy R Morgan; Marc G Ghany; Chihiro Morishima; Kristin K Snow; Jules L Dienstag
Journal:  N Engl J Med       Date:  2008-12-04       Impact factor: 91.245

5.  Re-treatment of patients with chronic hepatitis C who do not respond to peginterferon-alpha2b: a randomized trial.

Authors:  Donald M Jensen; Patrick Marcellin; Bradley Freilich; Pietro Andreone; Adrian Di Bisceglie; Carlos E Brandão-Mello; K Rajender Reddy; Antonio Craxi; Antonio Olveira Martin; Gerlinde Teuber; Diethelm Messinger; James A Thommes; Andreas Tietz
Journal:  Ann Intern Med       Date:  2009-04-21       Impact factor: 25.391

6.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.

Authors:  Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu
Journal:  N Engl J Med       Date:  2002-09-26       Impact factor: 91.245

7.  Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C.

Authors:  John G McHutchison; Michael Manns; Keyur Patel; Thierry Poynard; Karen L Lindsay; Christian Trepo; Jules Dienstag; William M Lee; Carmen Mak; Jean-Jacques Garaud; Janice K Albrecht
Journal:  Gastroenterology       Date:  2002-10       Impact factor: 22.682

8.  Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy.

Authors:  Thierry Poynard; Massimo Colombo; Jordi Bruix; Eugene Schiff; Ruben Terg; Steven Flamm; Ricardo Moreno-Otero; Flair Carrilho; Warren Schmidt; Thomas Berg; Thomas McGarrity; E Jenny Heathcote; Fernando Gonçales; Moises Diago; Antonio Craxi; Marcelo Silva; Pierre Bedossa; Pabak Mukhopadhyay; Louis Griffel; Margaret Burroughs; Clifford Brass; Janice Albrecht
Journal:  Gastroenterology       Date:  2009-01-22       Impact factor: 22.682

9.  Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.

Authors:  Stephanos J Hadziyannis; Hoel Sette; Timothy R Morgan; Vijayan Balan; Moises Diago; Patrick Marcellin; Giuliano Ramadori; Henry Bodenheimer; David Bernstein; Mario Rizzetto; Stefan Zeuzem; Paul J Pockros; Amy Lin; Andrew M Ackrill
Journal:  Ann Intern Med       Date:  2004-03-02       Impact factor: 25.391

10.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance.

Authors:  Dongliang Ge; Jacques Fellay; Alexander J Thompson; Jason S Simon; Kevin V Shianna; Thomas J Urban; Erin L Heinzen; Ping Qiu; Arthur H Bertelsen; Andrew J Muir; Mark Sulkowski; John G McHutchison; David B Goldstein
Journal:  Nature       Date:  2009-08-16       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.